Immunogenicity of anthracyclines: moving towards more personalized medicine

被引：103

作者：

Apetoh, Lionel ^{[1
]}

Mignot, Grgoire ^{[1
]}

Panaretakis, Theocharis ^{[2
]}

Kroemer, Guido ^{[2
]}

Zitvogel, Laurence ^{[1
]}

机构：

[1] Inst Gustave Roussy, INSERM, U805, F-94805 Villejuif, France

[2] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France

来源：

TRENDS IN MOLECULAR MEDICINE | 2008年 / 14卷 / 04期

关键词：

D O I：

10.1016/j.molmed.2008.02.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The current method of cancer management takes into account tumor-related factors to predict therapeutic outcome. However, recent evidence indicates that the host immune system also contributes to therapeutic outcome. Here, we highlight anthracyclines, which have been used to treat a broad range of cancers since the 1960s, as an example of an anticancer treatment that can boost the host's immune system to improve the efficacy of chemotherapy. It has recently been revealed that the translocation of calreticulin to the plasma membrane in tumor cells and the release of high-mobility-group box 1 (HMGB1) by tumor cells are two key post-transcriptional events required for the immunogenicity of anthracyclines. These discoveries represent a conceptual advance in the understanding of the mechanisms underlying the immunogenicity of anthracyclines. We review the effects of anthracyclines on the host immune system and discuss how this knowledge can be exploited for anticancer therapy.

引用

页码：141 / 151

页数：11

共 122 条

[1] Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].

Albert, ML ;

Sauter, B ;

Bhardwaj, N .

NATURE, 1998, 392 (6671) :86-89

[2] Tumor-specific killer cells in paraneoplastic cerebellar degeneration [J].

Albert, ML ;

Darnell, JC ;

Bender, A ;

Francisco, LM ;

Bhardwaj, N ;

Darnell, RB .

NATURE MEDICINE, 1998, 4 (11) :1321-1324

[3] PHASE-I CLINICAL-TRIAL OF MITOXANTRONE - A NEW ANTHRACENEDIONE ANTI-CANCER DRUG [J].

ALBERTS, DS ;

GRIFFITH, KS ;

GOODMAN, GE ;

HERMAN, TS ;

MURRAY, E .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1980, 5 (01) :11-15

[4]

ALEXANIAN R, 1994, NEW ENGL J MED, V330, P484

[5] The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Criollo, Alfredo ;

Ortiz, Carla ;

Lidereau, Rosette ;

Mariette, Christophe ;

Chaput, Nathalie ;

Mira, Jean-Paul ;

Delaloge, Suzette ;

Andre, Fabrice ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

IMMUNOLOGICAL REVIEWS, 2007, 220 :47-59

[6] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[7] Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer [J].

Aragon-Ching, Jeanny B. ;

Williams, Kirsten M. ;

Gulley, James L. .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :4957-4971

[8] TLR4 mutations are associated with endotoxin hyporesponsiveness in humans [J].

Arbour, NC ;

Lorenz, E ;

Schutte, BC ;

Zabner, J ;

Kline, JN ;

Jones, M ;

Frees, K ;

Watt, JL ;

Schwartz, DA .

NATURE GENETICS, 2000, 25 (02) :187-+

[9]

ARLIN Z, 1990, LEUKEMIA, V4, P177

[10]

ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023

← 1 2 3 4 5 6 7 8 9 10 →